Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor-based regimen: week 24 phase 3 results from VIKING-3

机译：Dolutegravir在基于整合酶抑制剂治疗方案失败的受试者中的抗病毒活性：VIKING-3第24周第3期结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundVIKING-3 aimed to examine efficacy and safety of dolutegravir (DTG) 50 mg twice daily in patients with resistance to multiple ARV classes, including integrase inhibitors (INI).

机译：BackgroundVIKING-3旨在检查每日两次50 mg的多洛格韦（DTG）在对包括整合酶抑制剂（INI）在内的多种ARV类耐药的患者中的疗效和安全性。

著录项

期刊名称 Journal of the International AIDS Society
作者
G Nichols; A Mills; R Grossberg; A Lazzarin; F Maggiolo; J Molina; G Pialoux; D Wright; M Ait-Khaled; J Huang; C Vavro; B Wynne; J Yeo;
展开▼
作者单位

展开▼
年(卷),期 2012(15),Suppl 4
年度 2012
页码 18112
总页数 2
原文格式 PDF
正文语种
中图分类免疫学;病毒传染病;
关键词

相似文献

外文文献
中文文献
专利

1. Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor-based regimen: week 24 phase 3 results from VIKING-3 [J] . G Nichols, A Mills, R Grossberg, Journal of the International Aids Society . 2012,第Suppla4期

机译：Dolutegravir在基于整合酶抑制剂治疗方案失败的受试者中的抗病毒活性：VIKING-3第24周第3期结果
2. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study [J] . CastagnaA., MaggioloF., PencoG., The Journal of Infectious Diseases . 2014,第3期

机译：Dolutegravir在抗逆转录病毒治疗的耐raltegravir和/或elvitegravir的HIV-1患者中的应用：VIKING-3 III期研究的24周结果
3. Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age = 50 Years: Final 96-Week Results of the NEAT022 Study [J] . Gatell Jose M., Assoumou Lambert, Stellbrink Hans-Juergen, Clinical infectious diseases . 2019,第4期

机译：从促进的蛋白酶抑制剂的基于促进蛋白酶抑制剂的方案的直接与病毒学抑制的患者在病变抑制的患者中的方案，高血管内风险或年龄较高的患者。= 50年：Neat022研究的最终96周的结果
4. Reliability of phased-mission systems subject to competing failures [C] . Wang Chaonan, Xing Liudong, Levitin Gregory 2013 Proceedings - Annual Reliability and Maintainability Symposium . 2013

机译：受相继故障影响的相控系统的可靠性
5. Clinical Effectiveness of Integrase Strand Transfer Inhibitor-based Antiretroviral Regimens in a Pooled Cohort of North American Adults [D] . Lu, Haidong . 2020

机译：北美成人汇集群组中整合酶链转移抑制剂的抗逆转录病毒方案的临床疗效
6. Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study [O] . Antonella Castagna, Franco Maggiolo, Giovanni Penco, -1

机译：Dolutegravir在抗逆转录病毒经验丰富的抗Raltegravir和/或Elvitegravir的HIV-1患者中的应用：VIKING-3 III期研究的24周结果
7. Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor-based regimen: week 24 phase 3 results from VIKING-3 [O] . Mills A, Nichols G, Grossberg R, 2012

机译：基于整合酶抑制剂治疗方案失败的受试者中dolutegravir的抗病毒活性：第24周第3阶段结果来自VIKING-3
8. Evaluation of In Vitro Cross-Reactivity to Avian H5N1 and Pandemic H1N1 2009 Influenza Following Prime Boost Regimens of Seasonal Influenza Vaccination in Healthy Human Subjects: A Randomised Trial. [R] . Bethell, D., Saunders, D., Jongkaewwattana, A., 2013

机译：在健康人类受试者中季节性流感疫苗接种的prime Boost方案后对禽流感H5N1和甲型H1N1流感的体外交叉反应性的评估：随机试验。

Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor-based regimen: week 24 phase 3 results from VIKING-3

摘要

著录项

相似文献

相关主题

期刊订阅